Navigating Contradictions: MAGiC Catheter's U.S. Adoption Timeline and Market Potential Unveiled

None



Revenue Growth and Commercial Progress:
- Stereotaxis reported 9% year-over-year growth in revenue for Q1 2025, with a focus on growing recurring revenue within its Map-iT portfolio.
- The growth was driven by the increasing adoption of Map-iT catheters, which experienced a 30% sequential increase in sales in the U.S., and the commercialization of the MAGiC catheter in Europe, which is expected to generate significant recurring revenue in the coming quarters.

Expansion into Europe with MAGiC Catheter:
- Stereotaxis received European approval for the MAGiC catheter and began commercial efforts, initially reaching over 20% of hospital customers with administrative submissions.
- The initial adoption of MAGiC is expected to generate a couple hundred thousand dollars of revenue this quarter and reach approximately $1 million per quarter by year-end, contributing to revenue growth.

Innovation and Product Pipeline:
- The company has multiple products in active regulatory review, with expectations for U.S. regulatory approval for MAGiC in the second half of the year and for GenesisX in the summer.
- This robust product pipeline is aimed at expanding robotic system growth, with the expectation of steady Genesis orders and additional GenesisX orders building on this base.

Operational and Financial Performance:
- Recurring revenue grew by 38% to $5.5 million, while system revenue was $2 million, compared to the previous year.
- Adjusted operating loss was $2.7 million, with negative free cash flow of $1.8 million, reflecting the ongoing investment in innovation and regulatory processes.